Journal: BMC Microbiology

Article Title: Pathogenic signatures and therapeutic evaluation of emergent MPXV Clade Ib in low-susceptibility and immunocompromised mouse models

doi: 10.1186/s12866-026-05273-4

Figure Lengend Snippet: Validation of AGB6, STAT1 −/− , and C57BL/6 Mice for MPXV Clade Ib Drug Evaluation. a : Mice were infected with MPXV Clade Ib via intranasal administration at a dose of 2 × 10 5 pfu/50 µl ( n = 3–5 mice per group). Tecovirimat (10 mg/kg) was administered intragastrically once daily starting from the day of infection, while the control group received an equal volume of vehicle alone. Mouse status was monitored daily and body weight was recorded post-infection. Mice were euthanized at appropriate time points for subsequent assays. b , d , f : Changes in mouse body weight post-viral infection (expressed as the percentage loss relative to initial body weight) (analyzed by multiple t test). c , e , g : Viral loads in mouse lung tissues, with titers expressed as PFU equivalents/g of tissue. h : Hematoxylin-eosin (HE) staining of mouse lung tissues. Orange arrows indicate bronchial necrosis; yellow arrows indicate peribronchial epithelioid cell hyperplasia; blue arrows indicate fibrosis; red arrows indicate inflammatory cell infiltration; green arrows indicate necrotic tissue debris and inflammatory cells in the bronchial lumen; gray arrows indicate pulmonary edema; cyan arrows indicate hemorrhage; black arrows indicate alveolar wall thickening. The right panel (bars = 1000 μm) shows the magnified view of the boxed area in the left panel (bars = 100 μm). i : Immunohistochemistry (IHC) staining of MPXV A29 protein in mouse lung tissues on day 7 post-infection. The right panel (bars = 100 μm) shows the magnified view of the dashed box area in the left panel (bars = 1000 μm). j , k , l : Quantitative analysis of viral protein-positive signals in Fig. i was performed using the color deconvolution method in Image J software

Article Snippet: Tecovirimat was obtained from MedChemExpress (MCE: HY-14805).

Techniques: Biomarker Discovery, Infection, Control, Staining, Immunohistochemistry, Software

Journal: bioRxiv

Article Title: Dissecting the neurotropism and neurovirulence of MPXV using human stem cell-based models

doi: 10.1101/2023.08.25.554849

Figure Lengend Snippet: a , Depiction of the chemical formula of tecovirimat (Tpoxx). b, Representative image of astrocytes treated with 5µM Tpoxx. (scale bar = 100 µm). c, Cell viability of astrocytes treated with the corresponding concentration of Tpoxx. d, In a single-cycle replication assay, astrocytes were infected with MPXV and treated with a serial dilution of Tpoxx for 48 hrs. Plaque forming assay was used to determine MPXV titers upon Tpoxx treatment. IC50 is indicated. e, Astrocytes (GFAP+, grey) were fixed 48 hours post infection and infection was visualised with immunofluorescence staining against MPXV antigen (red). f, Infection percentage in astrocytes upon Tpoxx treatment was quantified. g , Reverse transcription quantitative polymerase chain reaction of senescence genes in hPSC-derived astrocytes (n = 3 independent samples for each cell type). Statistical analysis was performed using one-way ANOVA with Dunnett’s correction for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. All data represent mean ± SD. Circles and triangles represent three biological replicates from two independent experiments.

Article Snippet: After the washing steps, fresh astrocyte medium with a serial dilution of tecovirimat (Selleckchem) was added to the cells.

Techniques: Concentration Assay, Infection, Serial Dilution, Immunofluorescence, Staining, Reverse Transcription, Real-time Polymerase Chain Reaction, Derivative Assay

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Pharmacologically inactive metabolites of Tecovirimat.

Article Snippet: Safety and pharmacokinetic parameter evaluation of oral Tecovirimat when administered for 28 days (Recruiting; Smallpox; Oral Tecovirimat (600 mg) two times a day for 28 days and a single subcutaneous dose (0.5 mL) of JYNNEOS vaccine on day one and day 29) , NCT04957485 (SIGA Technologies and United States Department of Defense; United States) , 2 (Interventional; Randomized; 445; Matching placebo of oral Tecovirimat and JYNNEOS vaccine) , PP: Treatment; PO: Geometric mean titer of vaccinia virus-neutralizing antibodies; SSD: 5 January 2022; SCD: 31 October 2022; LU: 27 May 2022; Results: Not available.

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Chemical structure of Tecovirimat monohydrate.

Article Snippet: Safety and pharmacokinetic parameter evaluation of oral Tecovirimat when administered for 28 days (Recruiting; Smallpox; Oral Tecovirimat (600 mg) two times a day for 28 days and a single subcutaneous dose (0.5 mL) of JYNNEOS vaccine on day one and day 29) , NCT04957485 (SIGA Technologies and United States Department of Defense; United States) , 2 (Interventional; Randomized; 445; Matching placebo of oral Tecovirimat and JYNNEOS vaccine) , PP: Treatment; PO: Geometric mean titer of vaccinia virus-neutralizing antibodies; SSD: 5 January 2022; SCD: 31 October 2022; LU: 27 May 2022; Results: Not available.

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: R x data of the EMA, USFDA, and Health Canada approved Tecovirimat.

Article Snippet: Safety and pharmacokinetic parameter evaluation of oral Tecovirimat when administered for 28 days (Recruiting; Smallpox; Oral Tecovirimat (600 mg) two times a day for 28 days and a single subcutaneous dose (0.5 mL) of JYNNEOS vaccine on day one and day 29) , NCT04957485 (SIGA Technologies and United States Department of Defense; United States) , 2 (Interventional; Randomized; 445; Matching placebo of oral Tecovirimat and JYNNEOS vaccine) , PP: Treatment; PO: Geometric mean titer of vaccinia virus-neutralizing antibodies; SSD: 5 January 2022; SCD: 31 October 2022; LU: 27 May 2022; Results: Not available.

Techniques: Virus

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: The development timeline of Tecovirimat.

Article Snippet: Safety and pharmacokinetic parameter evaluation of oral Tecovirimat when administered for 28 days (Recruiting; Smallpox; Oral Tecovirimat (600 mg) two times a day for 28 days and a single subcutaneous dose (0.5 mL) of JYNNEOS vaccine on day one and day 29) , NCT04957485 (SIGA Technologies and United States Department of Defense; United States) , 2 (Interventional; Randomized; 445; Matching placebo of oral Tecovirimat and JYNNEOS vaccine) , PP: Treatment; PO: Geometric mean titer of vaccinia virus-neutralizing antibodies; SSD: 5 January 2022; SCD: 31 October 2022; LU: 27 May 2022; Results: Not available.

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Mechanism of action of Tecovirimat.

Article Snippet: Safety and pharmacokinetic parameter evaluation of oral Tecovirimat when administered for 28 days (Recruiting; Smallpox; Oral Tecovirimat (600 mg) two times a day for 28 days and a single subcutaneous dose (0.5 mL) of JYNNEOS vaccine on day one and day 29) , NCT04957485 (SIGA Technologies and United States Department of Defense; United States) , 2 (Interventional; Randomized; 445; Matching placebo of oral Tecovirimat and JYNNEOS vaccine) , PP: Treatment; PO: Geometric mean titer of vaccinia virus-neutralizing antibodies; SSD: 5 January 2022; SCD: 31 October 2022; LU: 27 May 2022; Results: Not available.

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Important pharmacological parameters of Tecovirimat.

Article Snippet: Safety and pharmacokinetic parameter evaluation of oral Tecovirimat when administered for 28 days (Recruiting; Smallpox; Oral Tecovirimat (600 mg) two times a day for 28 days and a single subcutaneous dose (0.5 mL) of JYNNEOS vaccine on day one and day 29) , NCT04957485 (SIGA Technologies and United States Department of Defense; United States) , 2 (Interventional; Randomized; 445; Matching placebo of oral Tecovirimat and JYNNEOS vaccine) , PP: Treatment; PO: Geometric mean titer of vaccinia virus-neutralizing antibodies; SSD: 5 January 2022; SCD: 31 October 2022; LU: 27 May 2022; Results: Not available.

Techniques: Clinical Proteomics, Protein Binding

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Summary of the clinical studies of Tecovirimat.

Article Snippet: Safety and pharmacokinetic parameter evaluation of oral Tecovirimat when administered for 28 days (Recruiting; Smallpox; Oral Tecovirimat (600 mg) two times a day for 28 days and a single subcutaneous dose (0.5 mL) of JYNNEOS vaccine on day one and day 29) , NCT04957485 (SIGA Technologies and United States Department of Defense; United States) , 2 (Interventional; Randomized; 445; Matching placebo of oral Tecovirimat and JYNNEOS vaccine) , PP: Treatment; PO: Geometric mean titer of vaccinia virus-neutralizing antibodies; SSD: 5 January 2022; SCD: 31 October 2022; LU: 27 May 2022; Results: Not available.

Techniques: Comparison, Drug discovery, Capsules, Infection, Clinical Proteomics, Virus

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Summary of the critical patents/patent applications related to Tecovirimat.

Article Snippet: Safety and pharmacokinetic parameter evaluation of oral Tecovirimat when administered for 28 days (Recruiting; Smallpox; Oral Tecovirimat (600 mg) two times a day for 28 days and a single subcutaneous dose (0.5 mL) of JYNNEOS vaccine on day one and day 29) , NCT04957485 (SIGA Technologies and United States Department of Defense; United States) , 2 (Interventional; Randomized; 445; Matching placebo of oral Tecovirimat and JYNNEOS vaccine) , PP: Treatment; PO: Geometric mean titer of vaccinia virus-neutralizing antibodies; SSD: 5 January 2022; SCD: 31 October 2022; LU: 27 May 2022; Results: Not available.

Techniques: Infection, Formulation, Dispersion, Suspension, Virus

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Pharmacologically inactive metabolites of Tecovirimat.

Article Snippet: Tecovirimat monohydrate (Tecovirimat SIGA; SIGA Technologies) , Immediate-release capsule (Oral; 200 mg) , 6 January 2022 (Prescription) , Exclusivity information is not available. However, ten years of marketing exclusivity is possible , Smallpox, monkeypox, cowpox, and complications due to replication of vaccinia virus following vaccination against smallpox.

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Chemical structure of Tecovirimat monohydrate.

Article Snippet: Tecovirimat monohydrate (Tecovirimat SIGA; SIGA Technologies) , Immediate-release capsule (Oral; 200 mg) , 6 January 2022 (Prescription) , Exclusivity information is not available. However, ten years of marketing exclusivity is possible , Smallpox, monkeypox, cowpox, and complications due to replication of vaccinia virus following vaccination against smallpox.

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: R x data of the EMA, USFDA, and Health Canada approved Tecovirimat.

Article Snippet: Tecovirimat monohydrate (Tecovirimat SIGA; SIGA Technologies) , Immediate-release capsule (Oral; 200 mg) , 6 January 2022 (Prescription) , Exclusivity information is not available. However, ten years of marketing exclusivity is possible , Smallpox, monkeypox, cowpox, and complications due to replication of vaccinia virus following vaccination against smallpox.

Techniques: Virus

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: The development timeline of Tecovirimat.

Article Snippet: Tecovirimat monohydrate (Tecovirimat SIGA; SIGA Technologies) , Immediate-release capsule (Oral; 200 mg) , 6 January 2022 (Prescription) , Exclusivity information is not available. However, ten years of marketing exclusivity is possible , Smallpox, monkeypox, cowpox, and complications due to replication of vaccinia virus following vaccination against smallpox.

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Mechanism of action of Tecovirimat.

Article Snippet: Tecovirimat monohydrate (Tecovirimat SIGA; SIGA Technologies) , Immediate-release capsule (Oral; 200 mg) , 6 January 2022 (Prescription) , Exclusivity information is not available. However, ten years of marketing exclusivity is possible , Smallpox, monkeypox, cowpox, and complications due to replication of vaccinia virus following vaccination against smallpox.

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Important pharmacological parameters of Tecovirimat.

Article Snippet: Tecovirimat monohydrate (Tecovirimat SIGA; SIGA Technologies) , Immediate-release capsule (Oral; 200 mg) , 6 January 2022 (Prescription) , Exclusivity information is not available. However, ten years of marketing exclusivity is possible , Smallpox, monkeypox, cowpox, and complications due to replication of vaccinia virus following vaccination against smallpox.

Techniques: Clinical Proteomics, Protein Binding

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Summary of the clinical studies of Tecovirimat.

Article Snippet: Tecovirimat monohydrate (Tecovirimat SIGA; SIGA Technologies) , Immediate-release capsule (Oral; 200 mg) , 6 January 2022 (Prescription) , Exclusivity information is not available. However, ten years of marketing exclusivity is possible , Smallpox, monkeypox, cowpox, and complications due to replication of vaccinia virus following vaccination against smallpox.

Techniques: Comparison, Drug discovery, Capsules, Infection, Clinical Proteomics, Virus

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Summary of the critical patents/patent applications related to Tecovirimat.

Article Snippet: Tecovirimat monohydrate (Tecovirimat SIGA; SIGA Technologies) , Immediate-release capsule (Oral; 200 mg) , 6 January 2022 (Prescription) , Exclusivity information is not available. However, ten years of marketing exclusivity is possible , Smallpox, monkeypox, cowpox, and complications due to replication of vaccinia virus following vaccination against smallpox.

Techniques: Infection, Formulation, Dispersion, Suspension, Virus

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: R x data of the EMA, USFDA, and Health Canada approved Tecovirimat.

Article Snippet: SIGA Technologies have developed TPOXX (capsule and intravenous dosage forms of Tecovirimat) in collaboration with the Biomedical Advances Research and Development Authority (BARDA) of the US Department of Health and Human Services.

Techniques: Virus

Journal: Expert Review of Anti-Infective Therapy

Article Title: An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications

doi: 10.1080/14787210.2020.1819791

Figure Lengend Snippet: Molecular structure of tecovirimat (ST-246; 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide)

Article Snippet: We have recently entered into a collaboration with Turnstone Biologics to provide tecovirimat in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform [ ].

Techniques:

Journal: Expert Review of Anti-Infective Therapy

Article Title: An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications

doi: 10.1080/14787210.2020.1819791

Figure Lengend Snippet: Tecovirimat selectivity, and spectrum of antiviral activity

Article Snippet: We have recently entered into a collaboration with Turnstone Biologics to provide tecovirimat in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform [ ].

Techniques: Virus

Journal: Expert Review of Anti-Infective Therapy

Article Title: An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications

doi: 10.1080/14787210.2020.1819791

Figure Lengend Snippet: The molecular mechanism of action of tecovirimat. Image adapted from . Following viral entry into a permissive cell, orthopoxviruses replicate in the cytoplasm. New viral particles are formed in regions called virus factories. These immature virus (IV) particles undergo membrane envelopment to form infectious intracellular mature virus (IMV). IMV may be further enveloped with a double membrane layer derived from early endosomes or trans-Golgi network (TGN) to form intracellular enveloped virus (IEV). These triple membrane-enveloped particles may then be transported to the cell surface where their outermost membrane fuses with the cytoplasmic membrane, releasing the virions as either cell-associated enveloped virus (CEV) which remain associated with the cell membrane, or extracellular enveloped virus (EEV), which disseminate from the site of infection . The envelopment of IMV to form IEV requires the participation of several viral proteins including the VP37 protein, which is the target of tecovirimat. Inhibition of the VP37 protein prevents the formation of IEV from IMV

Article Snippet: We have recently entered into a collaboration with Turnstone Biologics to provide tecovirimat in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform [ ].

Techniques: Virus, Membrane, Derivative Assay, Infection, Inhibition

Journal: Expert Review of Anti-Infective Therapy

Article Title: An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications

doi: 10.1080/14787210.2020.1819791

Figure Lengend Snippet: Comparison of the course of smallpox in humans with monkeypox in NHPs and rabbitpox in rabbits. In evaluating the non-human primate model for human smallpox for demonstrating the efficacy of antiviral therapeutics, a number of parameters have to be considered: First, it is important to determine the stage of disease progression during the course of human smallpox at which treatment would no longer be considered prophylactic, but therapeutic. The most distinctive and unambiguous identification of smallpox was the appearance of a synchronous, centrifugal rash that progressed to pustules beginning a few days after severe fever. The time course and associated pathology of monkeypoxvirus in the non-human primate versus human smallpox is nearly identical from the secondary viremia onward. In the intravenous challenge non-human primate model, lesions appear 3–4 days post-challenge and continue to increase in number and progress through stages typical of human smallpox until death. In this model a uniformly lethal challenge of 5 × 10 7 plaque-forming units was used. At this challenge dose all animals in our pivotal NHP efficacy studies showed signs of illness by 4 days following challenge at which time tecovirimat intervention is considered therapeutic. Recent literature also suggests that rabbitpox disease in rabbits closely mimics the stages of smallpox disease in humans . After the initial infection, there is a symptom-free incubation period, followed by fever and the dissemination of virus in the blood and the establishment of a secondary systemic infection, followed by death. Following the USFDA recommendation at the 2011 advisory committee the intradermal challenge model was used for evaluation of tecovirimat efficacy. In this model a lethal viral challenge of 1,000 plaque-forming units of rabbitpox virus was chosen. The trigger in this model was different from the non-human primate model, since most rabbits die quickly, before developing lesions. The therapeutic trigger used in this model is fever, which is always observed prior to day 4. Therefore treatment started at day 4 in the rabbit models

Article Snippet: We have recently entered into a collaboration with Turnstone Biologics to provide tecovirimat in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform [ ].

Techniques: Comparison, Biomarker Discovery, Infection, Incubation, Virus

Journal: Expert Review of Anti-Infective Therapy

Article Title: An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications

doi: 10.1080/14787210.2020.1819791

Figure Lengend Snippet: Summary of studies in the clinical development of tecovirimat

Article Snippet: We have recently entered into a collaboration with Turnstone Biologics to provide tecovirimat in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform [ ].

Techniques: Capsules

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Pharmacologically inactive metabolites of Tecovirimat.

Article Snippet: SIGA Technologies is also developing an oral suspension formulation of Tecovirimat in collaboration with BARDA [ ].

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Chemical structure of Tecovirimat monohydrate.

Article Snippet: SIGA Technologies is also developing an oral suspension formulation of Tecovirimat in collaboration with BARDA [ ].

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: R x data of the EMA, USFDA, and Health Canada approved Tecovirimat.

Article Snippet: SIGA Technologies is also developing an oral suspension formulation of Tecovirimat in collaboration with BARDA [ ].

Techniques: Virus

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: The development timeline of Tecovirimat.

Article Snippet: SIGA Technologies is also developing an oral suspension formulation of Tecovirimat in collaboration with BARDA [ ].

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Mechanism of action of Tecovirimat.

Article Snippet: SIGA Technologies is also developing an oral suspension formulation of Tecovirimat in collaboration with BARDA [ ].

Techniques:

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Important pharmacological parameters of Tecovirimat.

Article Snippet: SIGA Technologies is also developing an oral suspension formulation of Tecovirimat in collaboration with BARDA [ ].

Techniques: Clinical Proteomics, Protein Binding

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Summary of the clinical studies of Tecovirimat.

Article Snippet: SIGA Technologies is also developing an oral suspension formulation of Tecovirimat in collaboration with BARDA [ ].

Techniques: Comparison, Drug discovery, Capsules, Infection, Clinical Proteomics, Virus

Journal: Viruses

Article Title: A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

doi: 10.3390/v14091870

Figure Lengend Snippet: Summary of the critical patents/patent applications related to Tecovirimat.

Article Snippet: SIGA Technologies is also developing an oral suspension formulation of Tecovirimat in collaboration with BARDA [ ].

Techniques: Infection, Formulation, Dispersion, Suspension, Virus